FDA Approves Glaxo's Raxibacumab as Inhalational Anthrax Treatment
Go back to FDA Approves Glaxo's Raxibacumab as Inhalational Anthrax Treatment| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 51.96 -0.92 (1.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $52.88 | 52 Week High | $45.58 | |||
| Open | $52.57 | 52 Week Low | $37.82 | |||
| Day High | $52.63 | P/E | N/A | |||
| Day Low | $51.86 | EPS | $0.00 | |||
| Volume | 3,582,337 | |||||
